Next, we used viable primary patient samples from these two cohorts to functionally assess our findings on the (PI3K)–AKT–mTOR axis, which is under PD-1 control in normal and malignant T cells, and our discovery of ACLY as a PD-1 target molecule in T-NHL. This evidence concerns the gene ACLY and non-Hodgkin lymphoma.